May 13, 2024

Digital health technologies for Charcot-Marie-Tooth (CMT) disease

We are thrilled to announce a new partnership with the Hereditary Neuropathy Foundation (HNF) to advance digital health technologies and biomarkers for Charcot-Marie-Tooth (CMT) disease.  

CMT is a genetically heterogeneous motor and sensory neuropathy characterized by progressive sensory loss and weakness of their legs and arms causing gait difficulties, frequent falls, balance impairment and hand weakness. 

As a starting point to our work work with HNF, BioSensics is proud to attend and sponsor the first CMT Clinical Trial Readiness Summit to be held June 7-8 in San Diego, CA. The Summit includes a digital wearable study sponsored by BioSensics and HNF to establish the initial clinical validity of BioSensics wearable devices, PAMSys and LEGSys, in CMT. 

“HNF has a strong history of being productive and impactful with the CMT stakeholder community utilizing the Global Registry for Inherited Neuropathies (GRIN) patient registry, our training & research in patient engagement and lessons learned from failed clinical trials for over a decade. This study is an exciting extension of this work,”said Allison Moore, Founder/CEO of HNF